How Fulcrum Therapeutics Protects Its Data

Source: Egnyte

By James Allgood

Security Lock

Chris Moxham, Ph.D., is the Chief Scientific Officer at Fulcrum Therapeutics, an innovative biotech addressing the causes of genetically defined disease. By developing treatments that address the root cause of disease, Fulcrum goes a step further than creating therapies that just manage symptoms and develops treatments that alter the genetic expression of disease, enabling life-changing outcomes.

Like many in the Life Sciences, the challenges that Fulcrum face are similar to those across the drug-development industry. The outsourcing of specialized tasks is increasing, and the data that is generated from these efforts is massive, often unstructured, and scattered across repositories. Maintaining GxP compliance, creating a secure environment for collaboration, and ensuring there is a single source of truth are becoming more and more of a hassle.

Read how Fulcrum has turned to technology to help automate many of these processes in order to streamline collaboration with third-parties and the organization of data into a single repository.


Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Drug Discovery Online? Subscribe today.

Subscribe to Drug Discovery Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Drug Discovery Online